The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2024 | Final results of the CLL2-BAAG trial: acalabrutinib, venetoclax, and obinutuzumab triplet in R/R CLL
Moritz Fürstenau, MD, University Hospital of Cologne, Cologne, Germany, discusses the final results of the CLL2-BAAG trial (NCT03787264), a Phase II study investigating the triple combination of acalabrutinib, venetoclax, and obinutuzumab in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL). Dr Fürstenau highlights that the measurable residual disease (MRD)-negative remission rate increased over time, with over 90% of patients achieving undetectable MRD. Remissions were long-lasting, with over 80% of patients remaining progression-free after three years. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
